Soligenix Inc. (NASDAQ: SNGX) has released peer-reviewed research demonstrating long-term high-temperature stability of its protein subunit vaccine platform targeting Ebola and Marburg viruses, a development that could significantly improve vaccine distribution in outbreak regions where maintaining cold chains is challenging.
The company's ThermoVax technology is designed to keep vaccines stable even when stored for extended periods at temperatures above 40°C, addressing a major barrier for current vaccines that require strict refrigeration between 2°C and 8°C. The World Health Organization estimates that more than 50% of vaccine doses globally are wasted each year due to breakdown in the cold chain, driven largely by inadequate temperature control during transport and storage (https://ibn.fm/WJsm6).
Soligenix, a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, published the findings in a peer-reviewed summary that highlights the potential of ThermoVax for emerging infectious diseases. The platform's broad applicability could extend beyond filoviruses to other pathogens, making it a valuable tool for epidemic preparedness.
The research comes as global health authorities emphasize the need for thermostable vaccines, particularly for diseases like Ebola and Marburg that often emerge in regions with limited refrigeration infrastructure. Current vaccines for these viruses require a continuous cold chain from manufacturer to patient, a logistical hurdle that has hampered vaccination efforts in past outbreaks.
Soligenix's approach uses a protein subunit formulation combined with a proprietary stabilization technology. The newly published data show that the vaccine candidates retain potency after prolonged exposure to high temperatures, meeting an unmet need identified by global health organizations.
The company notes that the ThermoVax platform has been designed to work with a range of vaccine types, potentially enabling rapid deployment in response to future outbreaks. By eliminating the dependency on cold storage, the technology could reduce waste, lower costs, and improve access in remote areas.
For more information, Soligenix provides updates in its newsroom at https://ibn.fm/SNGX.
